




Supplementary Figure 1: Flowchart of patients recused for molecular testing



Supplementary Figure 2: Types of samples used for molecular analyses in the frame of the Molecular Tumor Board




Supplementary Figure 3: Molecular analyses performed in the frame of the Molecular Tumor Board



- █ Loss of protein expression
- █ Pathogenic mutation
- █ Focal amplification
- █ Homozygous deletion
- █ Heterozygous deletion (+ mutation or loss of protein expression)

- Breast
- Ovary
- Head and neck
- Colorectal
- Cervix
- Prostate
- Lung
- Uterus
- Brain
- ACUP
- Liver
- Skin
- Bone
- Soft tissue
- Gall bladder
- Urothelial carcinon
- Other

Supplementary Figure 4: Focus on the PIK3/AKT/mTOR pathway alterations



Supplementary Figure 5: Reasons why patients were not included into a clinical trial

Other:

- Previously included in the study (n=2)
- Clinical trial closed (n=2)
- Therapeutic pause (n=1)
- Mutation not found in the most recent available sample (n=1)